RE:Lets try & stay on topic, this is a great and detailed reporbut will we live long enough?
our model assumes that pelareorep will advance through pivotal Phase III testing in at least two distinct oncology markets – HER2-negative/hormone receptor-positive metastatic breast cancer on which we have commented before, and advanced, metastatic pancreatic cancer that formed the basis of our analysis above – and that pelareorep can be approved and launched during the F2028-to-F2030 financial periods for both indications